2025
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcquired Aplastic AnemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-DependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failure
2023
Remission of severe myasthenia gravis after autologous stem cell transplantation
Schlatter M, Yandamuri S, O'Connor K, Nowak R, Pham M, Obaid A, Redman C, Provost M, McSweeney P, Pearlman M, Tees M, Bowen J, Nash R, Georges G. Remission of severe myasthenia gravis after autologous stem cell transplantation. Annals Of Clinical And Translational Neurology 2023, 10: 2105-2113. PMID: 37726935, PMCID: PMC10646993, DOI: 10.1002/acn3.51898.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationRefractory myasthenia gravisAutologous hematopoietic cell transplantationMyasthenia gravisCell transplantationAcetylcholine receptorsAutologous stem cell transplantationPhase 2 clinical trialAmerica (MGFA) clinical classificationMultiple immunomodulatory agentsRabbit antithymocyte globulinSevere myasthenia gravisAutoimmune neurological disordersHigh-dose chemotherapyMyasthenia Gravis FoundationNeuromuscular junction disordersStem cell transplantationTherapeutic plasma exchangeImmune cell subtypesDays of treatmentEffect of treatmentAntithymocyte globulinDisease activityComplete responseUnderwent treatment
2020
Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis
Ali N, Butt A, Altaf B, Adil SN, Shaikh MU. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Transplantation Proceedings 2020, 53: 386-390. PMID: 32773285, DOI: 10.1016/j.transproceed.2020.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, AplasticChildChild, PreschoolFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPostoperative ComplicationsRetrospective StudiesTransplantation ConditioningYoung AdultConceptsBone marrow stem cellsAplastic anemiaMarrow stem cellsOverall survivalAntithymocyte globulinAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantStem cellsStudy periodFrequency of GVHDHost disease (GVHD) prophylaxisStandard infection prophylaxisOnly curative optionBone marrow graftsStem cell transplantGranulocyte colony-stimulating factorColony-stimulating factorAga Khan UniversityAcute GVHDChronic GVHDConditioning regimenCurative optionTransplant outcomesAllogeneic transplantsConditioning regimens
2019
Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials
Schröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials. American Journal Of Transplantation 2019, 20: 564-572. PMID: 31452319, DOI: 10.1111/ajt.15580.Peer-Reviewed Original ResearchConceptsDeceased donor kidney transplant recipientsDonor kidney transplant recipientsKidney transplant recipientsGraft functionTransplant recipientsDeceased donor kidney transplantationDeceased donor kidney transplantAnti-C5 monoclonal antibodyDeceased donor recipientsRabbit antithymocyte globulinRate of DGFSerum creatinine reductionAdverse event incidenceDelayed graft functionDonor kidney transplantationDonor kidney transplantsIschemia-reperfusion injuryHigh-risk populationSafety/efficacyObservational human dataAntithymocyte globulinDGF rateKidney transplantationDonor recipientsKidney transplant
2015
Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients
Hricik DE, Formica RN, Nickerson P, Rush D, Fairchild RL, Poggio ED, Gibson IW, Wiebe C, Tinckam K, Bunnapradist S, Samaniego-Picota M, Brennan DC, Schröppel B, Gaber O, Armstrong B, Ikle D, Diop H, Bridges ND, Heeger PS. Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients. Journal Of The American Society Of Nephrology 2015, 26: 3114-3122. PMID: 25925687, PMCID: PMC4657844, DOI: 10.1681/asn.2014121234.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodiesAtrophyCalcineurin InhibitorsChemokine CXCL9Early Termination of Clinical TrialsFemaleFibrosisGraft RejectionHistocompatibility TestingHLA-DQ AntigensHumansImmunosuppression TherapyInterferon-gammaKidneyKidney TransplantationKidney TubulesMaleMiddle AgedNephritisProspective StudiesTacrolimusWithholding TreatmentYoung AdultConceptsDe novo donor-specific antibodiesKidney transplant recipientsAcute rejectionTransplant recipientsCNI withdrawalEpitope mismatchesTacrolimus withdrawalProtocol biopsiesCalcineurin inhibitorsDe novo DSADevelopment of dnDSANovo donor-specific antibodiesRabbit antithymocyte globulinTubular atrophy scoreDonor-specific antibodiesPrimary end pointIFN-γ ELISPOTDonor kidney transplantsUnacceptable rateAntithymocyte globulinCare immunosuppressionUrinary CXCL9Withdrawal armMycophenolate mofetilKidney transplant
2012
A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
Abu-Elmagd K, Costa G, Bond G, Soltys K, Martin L, Koritsky D, Cunha-Melo J, Sogawa H, Irish W, Tzakis A, Mazariegos G. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clinical Transplants 2012, 155-66. PMID: 23721018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlemtuzumabAnimalsAntibodies, Monoclonal, HumanizedAntilymphocyte SerumAntineoplastic AgentsFemaleGraft RejectionGraft SurvivalGraft vs Host DiseaseHumansImmunosuppressive AgentsIncidenceInfectionsIntestinesMaleMiddle AgedMorbidityPancreas TransplantationRabbitsStomachTransplantation, HomologousYoung AdultConceptsDose of rabbit antithymocyte globulinDe novo malignanciesRabbit antithymocyte globulinTacrolimus trough levelsLong-term immunosuppressionRe-transplantation rateLife-threatening infectionsLong-term survivalAntithymocyte globulinTacrolimus monotherapyAdrenal insufficiencyAllograft acceptanceRecipient pretreatmentTrough levelsImmunosuppressive strategiesSteroid-freeGraft lossSingle-doseAcute/chronic rejectionRe-transplantationGraft survivalMultivisceral transplantationSingle doseSerum sicknessAlemtuzumab pretreatment
2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2008
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildCyclosporineFemaleGraft SurvivalGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLiving DonorsMaleMycophenolic AcidMyeloablative AgonistsSiblingsTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousConceptsHematopoietic stem cell transplantationSickle cell diseaseRIC regimenCell transplantationCell diseaseEfficacy of HSCTHigh-risk sickle cell diseaseReduced-Intensity Hematopoietic Cell TransplantationAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning regimensEquine antithymocyte globulinHost disease (GVHD) prophylaxisTotal lymphoid irradiationAcceptable therapeutic optionHematopoietic cell transplantationGroup of patientsStem cell transplantationAntithymocyte globulinLymphoid irradiationConditioning regimenMycophenolate mofetilConditioning regimensDisease prophylaxisDonor engraftmentTherapeutic optionsHematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects
Krishnamurti L, Gupta D. Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects. Indian Journal Of Medical And Paediatric Oncology 2008, 29: 39-48. DOI: 10.4103/0971-5851.51444.Peer-Reviewed Original ResearchSickle cell diseaseRisk factorsAllogeneic bone marrow transplantationClass IIHematopoietic stem cell transplantationClass ITransplant related morbidityUnrelated donor transplantsHLA-identical donorHLA-identical siblingsStem cell transplantationBone marrow transplantationCourse of diseaseLong-term survivalYears of ageAntithymocyte globulinAllogeneic SCTTransplant outcomesDonor transplantsRelated morbidityMarrow transplantationCell transplantationCell diseaseProbability of survivalTerm survival
2007
Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression
Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, Mulligan DC. Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression. Clinical Transplantation 2007, 22: 309-315. PMID: 18482051, DOI: 10.1111/j.1399-0012.2007.00786.x.Peer-Reviewed Original ResearchConceptsSteroid avoidance immunosuppressionKidney-pancreas transplant recipientsOne-year biopsyKidney transplant recipientsBK nephropathySerum creatinineProtocol biopsiesRecipient ageTransplant recipientsGraft fibrosisUnadjusted logistic regression analysisLower body mass indexMultivariate logistic regression modelCI scoresPrimary kidney transplantsPancreas transplant recipientsBody mass indexInterstitial cellular infiltrateLogistic regression analysisLogistic regression modelsAcute rejectionAntigen mismatchesAntithymocyte globulinGraft outcomeKidney transplantDepletion of CD8 Memory T Cells for Induction of Tolerance of a Previously Transplanted Kidney Allograft
Koyama I, Nadazdin O, Boskovic S, Ochiai T, Smith R, Sykes M, Sogawa H, Murakami T, Strom T, Colvin R, Sachs D, Benichou G, Cosimi A, Kawai T. Depletion of CD8 Memory T Cells for Induction of Tolerance of a Previously Transplanted Kidney Allograft. American Journal Of Transplantation 2007, 7: 1055-1061. PMID: 17286617, PMCID: PMC3785402, DOI: 10.1111/j.1600-6143.2006.01703.x.Peer-Reviewed Original ResearchConceptsDonor bone marrow transplantationMemory T cellsCD8 memory T cellsInduce mixed chimerismTransplanted kidney allograftT cellsAllograft toleranceMixed chimerismKidney allograftsLow dose total body irradiationInduce renal allograft toleranceMemory T cell functionAnti-CD8 monoclonal antibodyLevels of memory T cellsDepletion of naive T cellsRenal allograft toleranceTotal body irradiationBone marrow transplantationAnti-CD154 antibodyNaive T cellsT cell functionTransplanted organInduction of toleranceConditioning regimenAntithymocyte globulin
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
1987
T-Lymphocyte Subsets in Renal Allograft Recipients Treated with Cyclosporine and Azathioprine
SUMPIO B, DWYER J, FLYE M. T-Lymphocyte Subsets in Renal Allograft Recipients Treated with Cyclosporine and Azathioprine. Annals Of Surgery 1987, 205: 49-53. PMID: 3541801, PMCID: PMC1492880, DOI: 10.1097/00000658-198701000-00009.Peer-Reviewed Original ResearchConceptsT4/T8 ratioRenal allograft recipientsT cell subsetsAntithymocyte globulinAllograft recipientsT8 ratioImmunosuppressive agentsPlasma levelsT lymphocytesNormal T4/T8 ratioDifferent immunosuppression protocolsT lymphocyte subsetsT4/T8Monoclonal antibody OKT3Cytomegalovirus titersImmunosuppression protocolsT4 subsetAntibody OKT3CyclosporinePatientsAzathioprineOnly azathioprineSelective ablationPrednisoneOKT3
1985
EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION
Bia M, Andiman W, Gaudio K, Kliger A, Siegel N, Smith D, Flye W. EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION. Transplantation 1985, 40: 610-614. PMID: 3000031, DOI: 10.1097/00007890-198512000-00007.Peer-Reviewed Original ResearchConceptsAntithymocyte globulinSteroid-resistant rejectionRenal transplant patientsCMV infectionAzathioprine groupCMV diseaseTransplant patientsEffect of ATGUse of ATGAzathioprine-treated patientsCMV antibody titersCyclosporine-treated patientsNumber of patientsCulture of urineEffect of treatmentATG therapyCadaveric recipientsInfection posttransplantationAdditional therapyCytomegalovirus infectionDrug regimensImmunosuppressive drugsAntibody titersAzathioprinePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply